Skip to main content
  • Cost-Effectiveness of Intraoperative-MRI Methods for Stereotactic Laser Amygdalohippocampotomy

    Final Number:

    Lucas R Philipp; Joel Eggebeen MS; Jon Timothy Willie MD PhD; Robert E. Gross MD PhD

    Study Design:

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: Conventional frame-based targeting systems for Stereotactic Laser Amygdalohippocampotomy (SLAH) requires multiple patient transfers between OR and MRI suites, allowing greater susceptibility to error in lesion targeting. Intraoperative MRI (iMRI) targeting systems (Clearpoint®, MRI Interventions) obviate the need for intraoperative transfers, but may be associated with additional costs. We therefore undertook a short-term economic evaluation of laser ablation procedures performed with the iMRI targeting system compared to conventional alternatives.

    Methods: 45 patient encounters were reviewed, including the 15 most recent of 3 groups: SLAH cases using the ClearPoint system, SLAH cases using the CRW frame, and open surgery cases. One-way MANOVA determined differences between groups for Total Cost incurred by the hospital. Costs were stratified by category. Significant multivariate effects were defined at alpha=0.05. Bonferroni alpha correction defined significant univariate effects (p<0.0038).

    Results: Significant differences were found for Total Costs (F[2,38]=10.48, p=0.0002), OR/Anesthesia Time (F[2,38]=54.90, p<0.0001), Hospitalization and Test Costs (p<0.0001). Differences in Total Cost comparing ClearPoint with CRW (99.62% CI: [-$1,221 , $17,630]), and ClearPoint with Open surgery (-$13,493 , $5,054) were not significantly different. ClearPoint OR/Anesthesia Time costs were $6,165 ($3,604 , $8,826) more than CRW. Hospitalization costs were higher for Open Surgery than ClearPoint or CRW (p<0.0001) which were not significantly different from each other (p=0.675). No differences were found for Medication or Procedure Costs. 43% of CRW patients required additional operations to achieve seizure freedom, versus only 23% among ClearPoint patients.

    Conclusions: Relative to open surgery, minimally invasive approaches offer measurable reductions in cost. Total Cost of ClearPoint likely falls between that of the comparators. OR/Anesthesia Time costs account for >75% of the total cost difference, representing a 5 hour difference in procedure length. Additionally, ClearPoint was associated with fewer reoperations. The ClearPoint iMRI targeting system is an economically sound alternative to established targeting methods and open surgery.

    Patient Care: This research is the only known economic evaluation of iMRI methods for SLAH, The present work suggests stereotactic methods which are associated with nonsignificant differences in cost relative to conventional methods, and a reduced need for reoperation in order to achieve target outcomes. Additionally, we highlight key areas for further cost reduction and future quality improvement.

    Learning Objectives: 1. Recognize the key advantages of iMRI methods in the context of laser ablative procedures 2. Appreciate important differences in the relative economic burden of each of the three surgical approaches discussed 3. Identify key areas for potential cost reduction and future quality improvement

    References: 1. Willie JT, Laxpati NG, Drane DL, et al. Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery. 2014;74(6):569-584; discussion 584-585. 2. Curry DJ, Gowda A, McNichols RJ, Wilfong AA: MR-guided stereotactic laser ablation of epileptogenic foci in children. Epilepsy Behav 24:408–414, 2012 3. Liscak R, Malikova H, Kalina M, Vojtech Z, Prochazka T, Marusic P, et al: Stereotactic radiofrequency amygdalohippocampectomy in the treatment of mesial temporal lobe epilepsy. Acta Neurochir (Wien) 152:1291–1298, 2010 4. Carpentier A, McNichols RJ, Stafford RJ, Itzcovitz J, Guichard J-P, Reizine D, et al: Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors. Neurosurgery 63:ONS21-28-29, 2008 5. Alexander E III, Moriarty TM, Kikinis R, Black P, Jolesz FM. The present and future role of intraoperative MRI in neurosurgical procedures. Stereotact Funct Neurosurg. 1997;68(1-4 pt 1):10–17. 6. Moriarty TM, Quinones-Hinojosa A, Larson PS, et al.. Frameless stereotactic neurosurgery using intraoperative magnetic resonance imaging: stereotactic brain biopsy. Neurosurgery. 2000;47(5):1138–1145. 7. Hall WA, Liu H, Martin AJ, Maxwell RE, Truwit CL. Brain biopsy sampling by using prospective stereotaxis and a trajectory guide. J Neurosurg. 2001;94(1):67–71. 8. De Salles AA, Frighetto L, Behnke E, et al.. Functional neurosurgery in the MRI environment. Minim Invasive Neurosurg. 2004;47(5):284–289. 9. Larson PS, Starr PA, Bates G, Tansey L, Richardson RM, Martin AJ. An optimized system for interventional magnetic resonance imaging-guided stereotactic surgery: preliminary evaluation of targeting accuracy. Neurosurgery. 2012;70(1 Suppl Operative):95-103; discussion 103. doi:10.1227/NEU.0b013e31822f4a91. 10. Starr PA, Martin AJ, Larson PS. Implantation of deep brain stimulator electrodes using interventional MRI. Neurosurg Clin N Am. 2009;20(2):193–203. 11. Martin AJ, Larson PS, Ostrem JL, et al.. Placement of deep brain stimulator electrodes using real-time high-field interventional magnetic resonance imaging. Magn Reson Med. 2005;54(5):1107–1114. 12. Ostrem JL, Ziman N, Galifianakis NB, et al. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson’s disease. J Neurosurg. 2016;124(4):908-916. doi:10.3171/2015.4.JNS15173. 13. Sidiropoulos C, Rammo R, Merker B, et al. Intraoperative MRI for deep brain stimulation lead placement in Parkinson’s disease: 1 year motor and neuropsychological outcomes. J Neurol. April 2016. doi:10.1007/s00415-016-8125-0. 14. Starr PA, Markun LC, Larson PS, Volz MM, Martin AJ, Ostrem JL. Interventional MRI-guided deep brain stimulation in pediatric dystonia: first experience with the ClearPoint system. J Neurosurg Pediatr. 2014;14(4):400-408. doi:10.3171/2014.6.PEDS13605.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy